The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

DICP, The Annals of Pharmacotherapy: Vol. 25, No. 9, pp. 978-986.
© 1991 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graves, N.
Right arrow Articles by Leppik, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graves, N.
Right arrow Articles by Leppik, I.

Research Articles

Antiepileptic medications in development

NM Graves and IE Leppik

Recently, there has been an increase in the research devoted to the study of investigational antiepileptic medications. This has led to extensive clinical trials of several new compounds. This review focuses on four of these antiepileptic medications in development: felbamate, gabapentin, lamotrigine, and vigabatrin. Each has a unique mechanism of action and great potential for the treatment of epilepsy.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
A. L Lofton and W. Klein-Schwartz
Evaluation of Lamotrigine Toxicity Reported to Poison Centers
Ann. Pharmacother., November 1, 2004; 38(11): 1811 - 1815.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1991 by Harvey Whitney Books Company.